title: Phase II study of cytarabine in Hodgkin's disease. The EORTC Lymphoma Cooperative Group.
abstract: Cytarabine was administered to 24 patients with previously treated Hodgkin's disease in the EORTC Lymphoma Cooperative Group. The drug was administered at the dose of 80 mg/m2 subcutaneously twice a day on 5 consecutive days every 3 weeks. The overall response rate was 17.6% (3 responses among 17 evaluable patients) with a short duration (2-6 months). The main toxicity was myelosuppression. Our experience in the EORTC Lymphoma Cooperative Group could not demonstrate a significant activity at this dose and schedule in Hodgkin's disease.
authors.affiliation: Division of Oncology, University Hospital, St Rafaël, Leuven, Belgium.
authors.forename: J
authors.initials: J
authors.lastname: Thomas
authors.forename: B
authors.initials: B
authors.lastname: de Pauw
authors.forename: A
authors.initials: A
authors.lastname: Hagenbeek
authors.forename: R
authors.initials: R
authors.lastname: Somers
authors.forename: P
authors.initials: P
authors.lastname: Carde
authors.forename: U
authors.initials: U
authors.lastname: Tirelli
authors.forename: N
authors.initials: N
authors.lastname: Duez
mesh_terms: D000328:Adult; D003561:Cytarabine / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged
chemical_list: D003561:Cytarabine